Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 842

1.

Application of an amyloid and tau classification system in subcortical vascular cognitive impairment patients.

Jang H, Kim HJ, Park S, Park YH, Choe Y, Cho H, Lyoo CH, Yoon U, Lee JS, Kim Y, Kim SJ, Kim JP, Jung YH, Ryu YH, Choi JY, Moon SH, Seong JK, DeCarli C, Weiner MW, Lockhart SN, Cho SH, Na DL, Seo SW.

Eur J Nucl Med Mol Imaging. 2019 Aug 31. doi: 10.1007/s00259-019-04498-y. [Epub ahead of print]

PMID:
31471715
2.

Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease.

Ewers M, Franzmeier N, Suárez-Calvet M, Morenas-Rodriguez E, Caballero MAA, Kleinberger G, Piccio L, Cruchaga C, Deming Y, Dichgans M, Trojanowski JQ, Shaw LM, Weiner MW, Haass C; Alzheimer’s Disease Neuroimaging Initiative.

Sci Transl Med. 2019 Aug 28;11(507). pii: eaav6221. doi: 10.1126/scitranslmed.aav6221.

PMID:
31462511
3.

The Influence of Cerebrospinal Fluid Abnormalities and APOE 4 on PHF-Tau Protein: Evidence From Voxel Analysis and Graph Theory.

Li Y, Yao Z, Yu Y, Fu Y, Zou Y, Hu B; Alzheimer’s Disease Neuroimaging Initiative.

Front Aging Neurosci. 2019 Aug 8;11:208. doi: 10.3389/fnagi.2019.00208. eCollection 2019.

4.

Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults.

Rl N, Ps I, N M, D T, S B, D T, N S, Ps A, Mw W; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2019 Jul 22;82:110-119. doi: 10.1016/j.neurobiolaging.2019.07.005. [Epub ahead of print]

PMID:
31437719
5.

Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers.

Nho K, Kueider-Paisley A, Ahmad S, MahmoudianDehkordi S, Arnold M, Risacher SL, Louie G, Blach C, Baillie R, Han X, Kastenmüller G, Trojanowski JQ, Shaw LM, Weiner MW, Doraiswamy PM, van Duijn C, Saykin AJ, Kaddurah-Daouk R; Alzheimer’s Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium.

JAMA Netw Open. 2019 Jul 3;2(7):e197978. doi: 10.1001/jamanetworkopen.2019.7978.

7.

Non-coding variability at the APOE locus contributes to the Alzheimer's risk.

Zhou X, Chen Y, Mok KY, Kwok TCY, Mok VCT, Guo Q, Ip FC, Chen Y, Mullapudi N; Alzheimer’s Disease Neuroimaging Initiative, Giusti-Rodríguez P, Sullivan PF, Hardy J, Fu AKY, Li Y, Ip NY.

Nat Commun. 2019 Jul 25;10(1):3310. doi: 10.1038/s41467-019-10945-z.

8.

Performing Sparse Regularization and Dimension Reduction Simultaneously in Multimodal Data Fusion.

Yang Z, Zhuang X, Bird C, Sreenivasan K, Mishra V, Banks S, Cordes D; Alzheimer's Disease Neuroimaging Initiative.

Front Neurosci. 2019 Jul 3;13:642. doi: 10.3389/fnins.2019.00642. eCollection 2019.

9.

Telomere Shortening in the Alzheimer's Disease Neuroimaging Initiative Cohort.

Nudelman KNH, Lin J, Lane KA, Nho K, Kim S, Faber KM, Risacher SL, Foroud TM, Gao S, Davis JW, Weiner MW, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2019;71(1):33-43. doi: 10.3233/JAD-190010.

PMID:
31322561
10.

Quantitative 18F-AV1451 Brain Tau PET Imaging in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Patients.

Zhao Q, Liu M, Ha L, Zhou Y; Alzheimer's Disease Neuroimaging Initiative.

Front Neurol. 2019 May 15;10:486. doi: 10.3389/fneur.2019.00486. eCollection 2019.

11.

APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points.

Toledo JB, Habes M, Sotiras A, Bjerke M, Fan Y, Weiner MW, Shaw LM, Davatzikos C, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2019;69(3):783-793. doi: 10.3233/JAD-181282.

PMID:
31127775
12.

The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory.

Franzmeier N, Rubinski A, Neitzel J, Ewers M; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Nat Commun. 2019 Apr 16;10(1):1766. doi: 10.1038/s41467-019-09564-5.

13.

Cognitive Performance in Parkinson's Disease in the Brain Health Registry.

Cholerton B, Weiner MW, Nosheny RL, Poston KL, Mackin RS, Tian L, Ashford JW, Montine TJ.

J Alzheimers Dis. 2019;68(3):1029-1038. doi: 10.3233/JAD-181009.

14.

A blood-based signature of cerebrospinal fluid Aβ1-42 status.

Goudey B, Fung BJ, Schieber C, Faux NG; Alzheimer’s Disease Metabolomics Consortium; Alzheimer’s Disease Neuroimaging Initiative.

Sci Rep. 2019 Mar 11;9(1):4163. doi: 10.1038/s41598-018-37149-7.

15.

Failure to detect an association between self-reported traumatic brain injury and Alzheimer's disease neuropathology and dementia.

Sugarman MA, McKee AC, Stein TD, Tripodis Y, Besser LM, Martin B, Palmisano JN, Steinberg EG, O'Connor MK, Au R, McClean M, Killiany R, Mez J, Weiner MW, Kowall NW, Stern RA, Alosco ML.

Alzheimers Dement. 2019 May;15(5):686-698. doi: 10.1016/j.jalz.2018.12.015. Epub 2019 Mar 7.

PMID:
30852157
16.

Diffusion MRI Indices and Their Relation to Cognitive Impairment in Brain Aging: The Updated Multi-protocol Approach in ADNI3.

Zavaliangos-Petropulu A, Nir TM, Thomopoulos SI, Reid RI, Bernstein MA, Borowski B, Jack CR Jr, Weiner MW, Jahanshad N, Thompson PM.

Front Neuroinform. 2019 Feb 19;13:2. doi: 10.3389/fninf.2019.00002. eCollection 2019.

17.

Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics.

Varatharajah Y, Ramanan VK, Iyer R, Vemuri P; Alzheimer’s Disease Neuroimaging Initiative.

Sci Rep. 2019 Feb 19;9(1):2235. doi: 10.1038/s41598-019-38793-3.

18.

Predicting Alzheimer's disease progression using multi-modal deep learning approach.

Lee G, Nho K, Kang B, Sohn KA, Kim D; for Alzheimer’s Disease Neuroimaging Initiative.

Sci Rep. 2019 Feb 13;9(1):1952. doi: 10.1038/s41598-018-37769-z.

19.

Polygenic hazard score, amyloid deposition and Alzheimer's neurodegeneration.

Tan CH, Bonham LW, Fan CC, Mormino EC, Sugrue LP, Broce IJ, Hess CP, Yokoyama JS, Rabinovici GD, Miller BL, Yaffe K, Schellenberg GD, Kauppi K, Holland D, McEvoy LK, Kukull WA, Tosun D, Weiner MW, Sperling RA, Bennett DA, Hyman BT, Andreassen OA, Dale AM, Desikan RS; Alzheimer’s Disease Neuroimaging Initiative.

Brain. 2019 Feb 1;142(2):460-470. doi: 10.1093/brain/awy327.

PMID:
30689776
20.

Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer's Dementia.

Schilling LP, Pascoal TA, Zimmer ER, Mathotaarachchi S, Shin M, de Mello Rieder CR, Gauthier S, Palmini A, Rosa-Neto P; Alzheimer’s Disease Neuroimaging Initiative.

Mol Neurobiol. 2019 Jul;56(7):4916-4924. doi: 10.1007/s12035-018-1405-1. Epub 2018 Nov 9.

PMID:
30414086
21.

Unsupervised online neuropsychological test performance for individuals with mild cognitive impairment and dementia: Results from the Brain Health Registry.

Mackin RS, Insel PS, Truran D, Finley S, Flenniken D, Nosheny R, Ulbright A, Comacho M, Bickford D, Harel B, Maruff P, Weiner MW.

Alzheimers Dement (Amst). 2018 Jun 21;10:573-582. doi: 10.1016/j.dadm.2018.05.005. eCollection 2018.

22.

Online study partner-reported cognitive decline in the Brain Health Registry.

Nosheny RL, Camacho MR, Insel PS, Flenniken D, Fockler J, Truran D, Finley S, Ulbricht A, Maruff P, Yaffe K, Mackin RS, Weiner MW.

Alzheimers Dement (N Y). 2018 Oct 15;4:565-574. doi: 10.1016/j.trci.2018.09.008. eCollection 2018.

23.

Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers.

Nho K, Kueider-Paisley A, MahmoudianDehkordi S, Arnold M, Risacher SL, Louie G, Blach C, Baillie R, Han X, Kastenmüller G, Jia W, Xie G, Ahmad S, Hankemeier T, van Duijn CM, Trojanowski JQ, Shaw LM, Weiner MW, Doraiswamy PM, Saykin AJ, Kaddurah-Daouk R; Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium.

Alzheimers Dement. 2019 Feb;15(2):232-244. doi: 10.1016/j.jalz.2018.08.012. Epub 2018 Oct 15.

24.

Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome.

MahmoudianDehkordi S, Arnold M, Nho K, Ahmad S, Jia W, Xie G, Louie G, Kueider-Paisley A, Moseley MA, Thompson JW, St John Williams L, Tenenbaum JD, Blach C, Baillie R, Han X, Bhattacharyya S, Toledo JB, Schafferer S, Klein S, Koal T, Risacher SL, Kling MA, Motsinger-Reif A, Rotroff DM, Jack J, Hankemeier T, Bennett DA, De Jager PL, Trojanowski JQ, Shaw LM, Weiner MW, Doraiswamy PM, van Duijn CM, Saykin AJ, Kastenmüller G, Kaddurah-Daouk R; Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium.

Alzheimers Dement. 2019 Jan;15(1):76-92. doi: 10.1016/j.jalz.2018.07.217. Epub 2018 Oct 15. Erratum in: Alzheimers Dement. 2019 Apr;15(4):604.

PMID:
30337151
25.

Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference.

Young AL, Marinescu RV, Oxtoby NP, Bocchetta M, Yong K, Firth NC, Cash DM, Thomas DL, Dick KM, Cardoso J, van Swieten J, Borroni B, Galimberti D, Masellis M, Tartaglia MC, Rowe JB, Graff C, Tagliavini F, Frisoni GB, Laforce R Jr, Finger E, de Mendonça A, Sorbi S, Warren JD, Crutch S, Fox NC, Ourselin S, Schott JM, Rohrer JD, Alexander DC; Genetic FTD Initiative (GENFI); Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Nat Commun. 2018 Oct 15;9(1):4273. doi: 10.1038/s41467-018-05892-0.

26.

Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.

Veitch DP, Weiner MW, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR Jr, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2019 Jan;15(1):106-152. doi: 10.1016/j.jalz.2018.08.005. Epub 2018 Oct 13. Review.

PMID:
30321505
27.

Total Sleep Time Interacts With Age to Predict Cognitive Performance Among Adults.

Mohlenhoff BS, Insel PS, Mackin RS, Neylan TC, Flenniken D, Nosheny R, Richards A, Maruff P, Weiner MW.

J Clin Sleep Med. 2018 Sep 15;14(9):1587-1594. doi: 10.5664/jcsm.7342.

28.

Sex-specific genetic predictors of Alzheimer's disease biomarkers.

Deming Y, Dumitrescu L, Barnes LL, Thambisetty M, Kunkle B, Gifford KA, Bush WS, Chibnik LB, Mukherjee S, De Jager PL, Kukull W, Huentelman M, Crane PK, Resnick SM, Keene CD, Montine TJ, Schellenberg GD, Haines JL, Zetterberg H, Blennow K, Larson EB, Johnson SC, Albert M, Moghekar A, Del Aguila JL, Fernandez MV, Budde J, Hassenstab J, Fagan AM, Riemenschneider M, Petersen RC, Minthon L, Chao MJ, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, Peskind ER, Li G, Davis LK, Sealock JM, Cox NJ; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Alzheimer Disease Genetics Consortium (ADGC), Goate AM, Bennett DA, Schneider JA, Jefferson AL, Cruchaga C, Hohman TJ.

Acta Neuropathol. 2018 Dec;136(6):857-872. doi: 10.1007/s00401-018-1881-4. Epub 2018 Jul 2.

PMID:
29967939
29.

Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment.

Gonzales MM, Insel PS, Nelson C, Tosun D, Schöll M, Mattsson N, Sacuiu S, Bickford D, Weiner MW, Mackin RS; Alzheimer's Disease Neuroimaging Initiative.

Int J Geriatr Psychiatry. 2018 Oct;33(10):1305-1311. doi: 10.1002/gps.4926. Epub 2018 Jun 28.

PMID:
29953668
30.

Response to Zywieck and Kirkby paper.

Weiner MW, Toga A, Harvey D, Donohue M, Beckett L.

Neurobiol Aging. 2018 Sep;69:298-299. doi: 10.1016/j.neurobiolaging.2018.05.031. Epub 2018 May 31. No abstract available.

PMID:
29929929
31.

Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using 18F-AV1451 Positron Emission Tomography Imaging.

Kim HJ, Park S, Cho H, Jang YK, San Lee J, Jang H, Kim Y, Kim KW, Ryu YH, Choi JY, Moon SH, Weiner MW, Jagust WJ, Rabinovici GD, DeCarli C, Lyoo CH, Na DL, Seo SW.

JAMA Neurol. 2018 Aug 1;75(8):999-1007. doi: 10.1001/jamaneurol.2018.0975.

32.

The Brain Health Registry: An internet-based platform for recruitment, assessment, and longitudinal monitoring of participants for neuroscience studies.

Weiner MW, Nosheny R, Camacho M, Truran-Sacrey D, Mackin RS, Flenniken D, Ulbricht A, Insel P, Finley S, Fockler J, Veitch D.

Alzheimers Dement. 2018 Aug;14(8):1063-1076. doi: 10.1016/j.jalz.2018.02.021. Epub 2018 May 10.

33.

Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials.

Iwatsubo T, Iwata A, Suzuki K, Ihara R, Arai H, Ishii K, Senda M, Ito K, Ikeuchi T, Kuwano R, Matsuda H; Japanese Alzheimer's Disease Neuroimaging Initiative, Sun CK, Beckett LA, Petersen RC, Weiner MW, Aisen PS, Donohue MC; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2018 Aug;14(8):1077-1087. doi: 10.1016/j.jalz.2018.03.009. Epub 2018 May 9.

34.

Systematic comparison of different techniques to measure hippocampal subfield volumes in ADNI2.

Mueller SG, Yushkevich PA, Das S, Wang L, Van Leemput K, Iglesias JE, Alpert K, Mezher A, Ng P, Paz K, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2017 Dec 27;17:1006-1018. doi: 10.1016/j.nicl.2017.12.036. eCollection 2018.

35.

Anosognosia predicts default mode network hypometabolism and clinical progression to dementia.

Therriault J, Ng KP, Pascoal TA, Mathotaarachchi S, Kang MS, Struyfs H, Shin M, Benedet AL, Walpola IC, Nair V, Gauthier S, Rosa-Neto P; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2018 Mar 13;90(11):e932-e939. doi: 10.1212/WNL.0000000000005120. Epub 2018 Feb 14.

36.

18F-florbetapir Positron Emission Tomography-determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery.

Klinger RY, James OG, Borges-Neto S, Bisanar T, Li YJ, Qi W, Berger M, Terrando N, Newman MF, Doraiswamy PM, Mathew JP; Alzheimer’s Disease Neuroimaging Initiative (ADNI) Study Group; Neurologic Outcomes Research Group (NORG).

Anesthesiology. 2018 Apr;128(4):728-744. doi: 10.1097/ALN.0000000000002103.

37.

Statistical tests and identifiability conditions for pooling and analyzing multisite datasets.

Zhou HH, Singh V, Johnson SC, Wahba G; Alzheimer’s Disease Neuroimaging Initiative.

Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):1481-1486. doi: 10.1073/pnas.1719747115. Epub 2018 Jan 31.

38.

Amyloid Associated Intermittent Network Disruptions in Cognitively Intact Older Subjects: Structural Connectivity Matters.

Mueller SG, Weiner MW.

Front Aging Neurosci. 2017 Dec 19;9:418. doi: 10.3389/fnagi.2017.00418. eCollection 2017.

39.

Pattern Discovery in Brain Imaging Genetics via SCCA Modeling with a Generic Non-convex Penalty.

Du L, Liu K, Yao X, Yan J, Risacher SL, Han J, Guo L, Saykin AJ, Shen L; Alzheimer’s Disease Neuroimaging Initiative.

Sci Rep. 2017 Oct 25;7(1):14052. doi: 10.1038/s41598-017-13930-y.

40.

Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline.

Risacher SL, Anderson WH, Charil A, Castelluccio PF, Shcherbinin S, Saykin AJ, Schwarz AJ; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2017 Nov 21;89(21):2176-2186. doi: 10.1212/WNL.0000000000004670. Epub 2017 Oct 25.

41.

Dementia Risk in Posttraumatic Stress Disorder: the Relevance of Sleep-Related Abnormalities in Brain Structure, Amyloid, and Inflammation.

Mohlenhoff BS, O'Donovan A, Weiner MW, Neylan TC.

Curr Psychiatry Rep. 2017 Oct 16;19(11):89. doi: 10.1007/s11920-017-0835-1. Review.

42.

Traumatic brain injury may not increase the risk of Alzheimer disease.

Weiner MW, Crane PK, Montine TJ, Bennett DA, Veitch DP.

Neurology. 2017 Oct 31;89(18):1923-1925. doi: 10.1212/WNL.0000000000004608. Epub 2017 Oct 4. Review.

43.

Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease.

Horgusluoglu-Moloch E, Nho K, Risacher SL, Kim S, Foroud T, Shaw LM, Trojanowski JQ, Aisen PS, Petersen RC, Jack CR Jr, Lovestone S, Simmons A, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative (ADNI).

Neurobiol Aging. 2017 Dec;60:92-103. doi: 10.1016/j.neurobiolaging.2017.08.010. Epub 2017 Aug 18.

44.

Corrigendum: Conversion Discriminative Analysis on Mild Cognitive Impairment Using Multiple Cortical Features from MR Images.

Guo S, Lai C, Wu C, Cen G; Alzheimer's Disease Neuroimaging Initiative.

Front Aging Neurosci. 2017 Sep 5;9:293. doi: 10.3389/fnagi.2017.00293. eCollection 2017.

45.

Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary Report.

Weiner MW, Harvey D, Hayes J, Landau SM, Aisen PS, Petersen RC, Tosun D, Veitch DP, Jack CR Jr, Decarli C, Saykin AJ, Grafman J, Neylan TC; Department of Defense Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement (N Y). 2017 Jun;3(2):177-188. doi: 10.1016/j.trci.2017.02.005.

46.

Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study.

Kinnunen KM, Cash DM, Poole T, Frost C, Benzinger TLS, Ahsan RL, Leung KK, Cardoso MJ, Modat M, Malone IB, Morris JC, Bateman RJ, Marcus DS, Goate A, Salloway SP, Correia S, Sperling RA, Chhatwal JP, Mayeux RP, Brickman AM, Martins RN, Farlow MR, Ghetti B, Saykin AJ, Jack CR Jr, Schofield PR, McDade E, Weiner MW, Ringman JM, Thompson PM, Masters CL, Rowe CC, Rossor MN, Ourselin S, Fox NC; Dominantly Inherited Alzheimer Network (DIAN).

Alzheimers Dement. 2018 Jan;14(1):43-53. doi: 10.1016/j.jalz.2017.06.2268. Epub 2017 Jul 22.

47.

 Cortical Atrophy is Associated with Accelerated Cognitive Decline in Mild Cognitive Impairment with Subsyndromal Depression.

Gonzales MM, Insel PS, Nelson C, Tosun D, Mattsson N, Mueller SG, Sacuiu S, Bickford D, Weiner MW, Mackin RS; Alzheimer's Disease Neuroimaging Initiative.

Am J Geriatr Psychiatry. 2017 Sep;25(9):980-991. doi: 10.1016/j.jagp.2017.04.011. Epub 2017 Apr 20.

PMID:
28629965
48.

Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.

Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS; Alzheimer’s Disease Neuroimaging Initiative.

JAMA. 2017 Jun 13;317(22):2305-2316. doi: 10.1001/jama.2017.6669.

49.

Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease.

Nho K, Kim S, Horgusluoglu E, Risacher SL, Shen L, Kim D, Lee S, Foroud T, Shaw LM, Trojanowski JQ, Aisen PS, Petersen RC, Jack CR Jr, Weiner MW, Green RC, Toga AW, Saykin AJ; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

BMC Med Genomics. 2017 May 24;10(Suppl 1):29. doi: 10.1186/s12920-017-0267-0.

50.

Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease.

Insel PS, Ossenkoppele R, Gessert D, Jagust W, Landau S, Hansson O, Weiner MW, Mattsson N; Alzheimer's Disease Neuroimaging Initiative.

Front Neurosci. 2017 May 17;11:281. doi: 10.3389/fnins.2017.00281. eCollection 2017.

Supplemental Content

Loading ...
Support Center